Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minute Insight: NHS Employs OCTAPUS AI To Predict Lung Cancer Recurrence

Executive Summary

The OCTAPUS AI study demonstrated that machine learning was a better tool than typical assessments used to predict recurrence of non-small cell lung cancer.

You may also be interested in...



Report Digest: Discussing What's Going On With Prostate Cancer Diagnosis And Treatment

In this edition of Report Digest, UK-based reporter Barnaby Pickering talks about the prostate cancer diagnostics and minimally invasive treatments markets with analyst Phil Greenfield. The two discuss ongoing developments in both treatment and diagnosis, while exploring driving and limiting factors for both.

Deals Shaping The Medical Industry, April 2022

In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2022. Data provided by Biomedtracker

Deals Shaping The Medtech Industry, April 2022

Medtech Insight's deal-making column is a survey of recent medtech transactions listed by relevant industry segment – in vitro diagnostics and medical devices  – and then categorized by type – acquisition, alliance, or financing. This month’s column covers deals announced in April 2022. Data provided by Biomedtracker.

Topics

UsernamePublicRestriction

Register

MT145329

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel